Ireland's GH Research Q2 net loss widens on higher R&D costs

GH Research

06/08/2026 12:58

Overview
Ireland biopharmaceutical firm's Q2 net loss widened yr/yr, with higher R&D and G&A expenses
Company's cash and marketable securities rose to $362.7 mln, aided by $117.5 mln offering
Company received FDA alignment on CMC and device plans for Phase 3 pivotal program

Outlook
GH Research targets initiation of global Phase 3 pivotal program for GH001 in 2026
GH Research expects further strengthening of US and EU mebufotenin patent estate

Result Drivers
R&D EXPENSES - Co said higher research and development expenses were mainly due to increased clinical development and employee costs
G&A EXPENSES - Co said higher general and administrative expenses were mainly due to increased professional fees

Company press release: ID:nGNX22XpYK

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.23
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for GH Research PLC is $37.00, about 27% above its August 5 closing price of $29.13

Reuters Recommended Reads
Aug 5 - Compass Pathways' Q2 loss widens on commercial readiness activity costs
Aug 5 - Context Therapeutics Q2 net loss widens on higher R&D costs
Aug 3 - Ireland's Jazz Pharma Q2 revenue beats estimates on Zepzelca higher sales

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)